Cargando…

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

Three long-acting muscarinic antagonists (LAMAs) are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease. The first LAMA, tiotropium, has been widely used over the last decade as a once-dai...

Descripción completa

Detalles Bibliográficos
Autor principal:	Jones, Paul W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381904/ https://www.ncbi.nlm.nih.gov/pubmed/25848244 http://dx.doi.org/10.2147/COPD.S76520

Ejemplares similares

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
por: Zhong, Jun, et al.
Publicado: (2014)

Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
por: Sims, Michael W, et al.
Publicado: (2011)

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
por: Jones, Paul W, et al.
Publicado: (2011)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
por: Matera, Maria Gabriella, et al.
Publicado: (2016)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
por: Singh, Dave, et al.
Publicado: (2017)

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD
por: Suppli Ulrik, Charlotte
Publicado: (2012)

Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022)

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
por: Moitra, Subhabrata, et al.
Publicado: (2015)

A comparison of the efficacy and safety of combined aclidinium bromide and formoterol fumarate in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis
por: Lu, Hong, et al.
Publicado: (2020)

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
por: D’Urzo, Anthony D., et al.
Publicado: (2019)

Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016)

A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study
por: Kostikas, Konstantinos, et al.
Publicado: (2020)

Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma
por: Alvarado-Gonzalez, Alcibey, et al.
Publicado: (2015)

Clinical use of aclidinium in patients with COPD
por: Reid, Debra J, et al.
Publicado: (2014)

Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting
por: Lange, Peter, et al.
Publicado: (2016)

Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study
por: Beier, Jutta, et al.
Publicado: (2013)

Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years
por: Karabis, Andreas, et al.
Publicado: (2014)

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
por: McGarvey, Lorcan, et al.
Publicado: (2016)

Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial
por: Wise, Robert A., et al.
Publicado: (2021)

Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review
por: Spyratos, Dionisios, et al.
Publicado: (2015)

The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
por: Wise, Robert A, et al.
Publicado: (2021)

Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study
por: Kamei, Tadashi, et al.
Publicado: (2019)

An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
por: Zhang, Hong, et al.
Publicado: (2022)

The Effect of Aclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study
por: Smith, Jaclyn A., et al.
Publicado: (2019)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
por: Singh, Dave, et al.
Publicado: (2014)

Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease
por: Panos, Ralph J
Publicado: (2013)

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
por: D’Urzo, Anthony D, et al.
Publicado: (2014)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
por: Contoli, Marco, et al.
Publicado: (2016)

Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
por: Yu, Suyun, et al.
Publicado: (2021)

A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink
por: Rebordosa, Cristina, et al.
Publicado: (2021)

Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease
por: Tanaka, Ken-Ichiro, et al.
Publicado: (2014)

Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
por: Ulrik, Charlotte Suppli
Publicado: (2012)

Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies
por: Wedzicha, Jadwiga A., et al.
Publicado: (2016)

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants
por: Li, Weimin, et al.
Publicado: (2023)

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies
por: Jones, Paul W., et al.
Publicado: (2016)

Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease
por: Jones, Paul W, et al.
Publicado: (2011)

Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease
por: Li, Xuan, et al.
Publicado: (2017)

Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Mehta, Rashmi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_74lpasd90cn9tjnp7pjjlpi8vn